Stockreport

Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease

Tarsus Pharmaceuticals, Inc.  (TARS) 
PDF – A pioneering investigational oral prophylactic approach designed to kill Lyme-infected ticks before disease transmission –  IRVINE, Calif., March 31, 2026 (GLOBE NEW [Read more]